Business Wire

Leyard Expands Investment in Europe with New Factory

Del

Leyard, a global leader in visualization products, today announced that it is expanding its investment in Europe and support for international customers with a new factory and showroom planned near Prešov, Slovakia.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160815005296/en/

Leyard strengthens European presence with new European factory and showroom (Photo: Business Wire)

Leyard strengthens European presence with new European factory and showroom (Photo: Business Wire)

The 3,119 square-meter (33,500 square-foot) building, slated for completion in early 2017, will enable Leyard to meet the growing demand for its digital displays and video walls from European customers, especially those who prefer to purchase digital display solutions built in the European Union (EU). The new factory will supplement Leyard’s existing facilities in Albi (France), Shenzhen and Beijing (China), and Beaverton (USA).

“Europe is a critical market for us as we expand our global presence,” said Robert Stewart, executive director of Leyard Europe. “The new factory will bring us even closer to our European, Russian, Middle Eastern and African customers while enabling us to extend high-quality manufacturing into a key region of the world.”

Located on a 10,000 square-meter (2.5-acre) parcel of land in an industrial park in the town of Záborské near Prešov, the new facility and will consist of a factory, office space, conference rooms and a cafeteria. It will also include a showroom displaying Leyard’s groundbreaking LED video walls, award-winning Planar display solutions and other advanced technology for customers and partners.

The city of Prešov is a growing hub for high-technology manufacturing, and Slovakia has been a member of the EU since 2004, currently holding the position of the presidency of the Council of the EU.

The opening of the factory comes on the heels of many successful Leyard installations across Europe including two new massive video walls at the La Salle des Emirats at the Palace of Nations, the European headquarters of the United Nations located in Geneva, Switzerland.

Leyard was named the market leader in narrow pixel pitch LED video wall displays in a new report by Futuresource Consulting. The company delivers a broad range of fine pitch LED video wall solutions including the recently launched and award-winning Leyard® TWA Series, a line of fine pitch LED video wall displays featuring a unique flat panel design, low power consumption and outstanding image quality. The Leyard® TVH Series with an advanced design for high reliability and the Planar® DirectLight™ LED Video Wall System, with front-serviceability and a unique off-board architecture, round out the company’s fine pitch LED portfolio, offering customers a wide range of fine pitch LED solutions for mission-critical reliability. Leyard’s line-up also includes several award-winning LCD display solutions including the industry-leading Clarity® Matrix™ LCD Video Wall System, 4K LCD displays lines including the Planar® UltraRes™ Series and Planar® EP Series , as well as interactive touch solutions ranging from 32-inch to 98-inch LCD displays and interactive LCD video walls up to a 350 inch diagonal.

For more information about Leyard display solutions, visit www.leyard.com.

About Leyard

Leyard Optoelectronic Co., Ltd. is a global leader in the design, production, distribution, and service of digital displays, video walls, and visualization products worldwide. Leyard has gained significant market share in fine pitch LED and offers indoor, outdoor, fixed, and creative displays, as well as other ancillary and lighting solutions for the urban environment. Used in various applications, such as broadcast, sports arenas, stadiums, advertisement networks, retail digital signage, control rooms, exhibitions, large scale events, and digital cultural experiences, Leyard enjoys marquee installations globally. Leyard was founded in 1995, is headquartered in Beijing, China, and is traded on the Shenzhen Stock Exchange (stock code: 300296). Forbes magazine (2013) named Leyard among “China’s Top 100 Most Potential Listed Companies.” Planar Systems was acquired by Leyard in 2015. For more information, visit www.leyard.com.

Contact information

Leyard Optoelectronic Co., Ltd.
EMEA, APAC and Latin America:
Desirée Cendón
marketing@leyardeurope.eu
or
North America:
Blu Print Public Relations
Kristin Whitney, 503-983-8080
kristin@bluprintpr.net
or
Leyard
Kim Brown
pr@planar.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-40211.12.2017 06:00Pressemelding

ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-402 (loncastuximab tesirine or “Lonca-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-402 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma Dr. Brad Kahl, M.D., Professor for Medical Oncology at the Washington University School of Medicine in St. Louis, said: “A significant number

GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske11.12.2017 05:01Pressemelding

GA Telesis, LLC (“GAT”) announces the launch of its Leveraged Finance Group (“LFG”) to provide secured aircraft financing for lessors, investors, and airlines. GAT has appointed David Lloyd and Nolan Heske as Managing Directors of LFG to pursue the development, execution and growth of this strategy. The LFG management team has over 35 years of combined experience in the aircraft and transportation finance sector. Prior to joining GAT, Mr. Lloyd and Mr. Heske cofounded Air Funding in 2016 to provide an alternative source of direct lending on commercial aircraft to lessors and airlines. Prior to Air Funding, David Lloyd spent 12 years at Carlson Capital as Head of Credit, Airlines & Aerospace. Mr. Lloyd was the group founder and was responsible for a portfolio with peak assets of $475 million. Mr. Lloyd also held executive positions at Credit Suisse and Chase Securities. No

AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun

Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30Pressemelding

Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30Pressemelding

Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom